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___________________________________________________________________________ Introduction:
Prostate cancer (CaP) is the most common visceral cancer diagnosed in men; it is the second leading cause of cancer related deaths in males in the United States and the Western world (1) . The lack of effective therapies for advanced CaP reflects to a large extent, the paucity of knowledge about the molecular pathways involved in CaP development. Thus, the identification of new predictive biomarkers will be important for improving clinical management, leading to improved survival of patients with CaP. Such molecular targets, especially those that are indicative of proliferation, invasiveness of the disease and survival of cancerous cells (even after chemotherapy) will also be excellent candidate targets for staging the disease and establishing effectiveness of therapeutic and chemopreventive intervention of CaP (2 ) .
The critical pathological processes that occur during the development and progression of human CaP and are known to confer aggressiveness to cancer cells are (i) abolishment of senescence of normal prostate epithelial cells (ii) self-renewablity of CaP cells even after chemotherapy and radiation and (iii) dysregulated cell cycle resulting in unchecked proliferation of cancer cells (3) (4) . Polycomb group (PcG) family of proteins (which form multimeric gene-repressing complexes) have been reported to be involve in self-renewablity, cell cycle regulation, and senescence (5) (6) (7) . Bmi-1 is a transcription repressor originally identified as a c-myc cooperating oncogene in murine lymphoma and has emerged as an important member of PcG family (8) . It has been shown to determine the proliferative potential of normal and cancer cells and is reported to be required for the selfrenewal of hematopoietic and neural stem cells (9) . The human Bmi-1 is located on the short arm of chromosome 10p13, a region known to be involved in translocations in various leukemias and rearrangements in malignant T-cell lymphomas (9) . Bmi-1 has been shown to be overexpressed in lymphomas, non-small cell lung cancer, B-cell non-Hodgkin's lymphoma, breast cancer, colorectal cancer and nasopharyngeal carcinoma (10) . Bmi-1 was has been showed to be a useful molecular marker for predicting occurrence of myelodysplastic syndrome and prognosis of the patients (11) . Cellular target genes of Bmi-1 have been identified and include ink4a and ink4b loci, encoding p16 INK4A , p19 ARF , and p15 INK4B (12) . Recently, Glinsky et al have shown that the activation of Bmi-1 might be associated with the malignant behavior of CaP cells (13) . In the current study, we provide evidence about the over-expression of Bmi-1 in human CaP cells (in particular in highly aggressive and androgen-independent cell types) and tissue specimens and show that this correlates with the clinical stages of human CaP. We also show that the over expression of Bmi-1 breaks the senescence of normal prostate epithelial cells as well as drives proliferation of CaP cells by regulating the expression of pro-survival and proliferation-associated genes such as Cyclin D1 and Bcl-2. We propose a role for Bmi-1 protein in CaP development and suggest its potential use as a biomarker in the clinical management of CaP.
Body
Under this section we provide information about the experimental design for tasks # 1-2 and materials and methods used to accomplish our objectives as stated in the proposal.
Experimental Design for Specific Aim #1.
We conducted the experiments to define the effect of overexpression and silencing of Bmi-1 gene in CaP cells.
For this purpose, we (a) knockdown the Bmi-1 gene by transfection of siRNA and (b) overexpressed the Bmi-1 gene by transfecting Bmi-1 construct (pbabe-Bmi-1 plasmid provided by Professor Chi Van Dang, Professor of Cell Biology, School of Medicine, The Johns Hopkins University, Baltimore, MD) in PC3 (androgeninsensitive), LNCaP (androgen-sensitive), CWR22R1 (androgen-sensitive) and normal prostate epithelial cells (PrEC) cells. We then studied the growth and viability of transfected cells in vitro by employing the MTT assay.
To investigate the effect of Bmi-1 gene on the rate of proliferation of CaP cells, we employed 3 [H]thymidine uptake assay. This assays measures the amount of 3 [H]thymidine taken up by dividing cells (for DNA synthesis) thus gives a measure of the rate of division or proliferation of cells. Bmi-1 silenced and Bmi-1 overexpressing CaP cells were cultured in presence of 3 [H]thymidine and 3 [H] thymidine uptake was measured by Liquid scintillation counter. These cells were also measured for DNA content. Since Bmi-1 was observed to increase the proliferative potential of CaP cells and to establish that Bmi-1 indeed was a driving force for proliferating cells, we investigated whether Bmi-1 has to potential to drive proliferation of normal prostate epithelial cells.
For this purpose, Bmi-1 was overexpressed in normal prostate epithelial cells (PrEC). We chose PrEC cells because under normal culture conditions, PrEC cells are known to replicate between 3-4 cycles and after 4 cycles, these cells enter into a mode of senescence. The break of senescence in normal epithelial cells is a hall mark of progression towards proliferation. As a control to study, another set of PrEC cells were transfected alone vector (pbabe). Further a microarray was performed with Bmi-1 silenced LNCaP cells to understand the mechanism of action of Bmi-1 in CaP cells. Experiments conducted under this aim provided information whether genes involved in proliferation are regulated by Bmi-1 gene. These data were validated by western blot analysis. We analyzed the expression level of Cyclin D1, p16 and Bcl-2 protein in CaP cells. Next we investigated whether the overexpression generates the data contrary to what was observed in Bmi-1 silenced cells. For this purpose Bmi-1 was overexpressed in LNCaP, PC-3 and DU145 cells by transfecting pbabe-Bmi-1 plasmid. Cell lysates prepared from these cells were analyzed for Cyclin D1, Bcl-2 and p16 proteins by employing western blot analysis. To understand the mechanism through which Bmi-1 regulates Cyclin D1, we carried out experiments on critical pathways which are already know to be associated with Cyclin D1 expression. This includes Wnt/-catenin signaling pathway. We asked whether Bmi-1 has any association with Wnt/-catenin signaling (which is itself reported to control Cyclin D1). Interestingly, we found that Bmi-1 overexpression causes an increase in the transcriptional activation of TCF-responsive element (a bio-marker of Wnt signaling) in CaP cells. Since Bcl-2 was observed to be modulated by Bmi-1, we investigated if Bmi-1 has any association with sonic hedgehog (SHH) pathway that is very well know to regulate Bcl-2. For this purpose we determined the expression level of Bcl-2 in Bmi-1-overexpressing and Bmi-1-silenced CaP cells in presence of Cyclopamine, a SHH pathway inhibitor. We also tested if re-introduction of Bmi-1 would restore the Bcl-2 levels in CaP cells pre-treated with cyclopamine (SHH inhibitor). Further, we investigated an association of tcf and Bcl-2 in CaP cells. We investigated the mechanism through which Bmi-1 drives the Tcf/Bcl-2 signaling in CaP cells.
Material and Methods:
Cell Lines: Normal prostate epithelial cell (PrEC) was procured from Cambrex. Virally transformed prostate epithelia cells (RWPE-1), PC-3, CWR22R1, DU-145 and LNCaP cancer cells were obtained from ATCC (Manassas, VA). Cells were cultured in appropriate media and were kept in a humidified atmosphere of 95% air and 5% CO 2 in an incubator at 37 o C.
Plasmids and siRNA:
The pbabe-Bmi-1 plasmid was a kind gift from Dr. Chi V. Dang (The John Hopkins University, Baltimore, MD). pbabe vector was purchased from Addgene Inc. (Cambridge, MA). Bmi-1-siRNA and scrambled siRNA were commercially purchased from Dharmacon (Lafayette, CO). Vector-based shRNA plasmid pGeneCLIP and pGeneCLIP-Bmi-1-shRNA were procured from SA Biosciences Corporation Statistical analysis. All measures were summarized as means ± SE. Measures were examined for the appropriateness of a normality assumption by density estimation (data not shown). Associations of categoric variables were evaluated using the Fisher's exact test. Sample correlations were estimated using Spearman's rank correlation. All tests were two-sided and conducted at the alpha = 0.05 significance level. All statistical analyses were performed with the S-plus, Professional Version 6.2 (Insightful Corp., Seattle, WA) software.
Key Research Accomplishments:
We proposed three sub-aims under specific aim # 1. Following is the list of work completed under 1-17 months proposed time as described in the Statement of Work:
Proposed Task 1. To establish the involvement of Bmi-1 in the proliferation of human CaP cells. Status
: Submitted as 1 st annual report
Proposed Task 2. To evaluate the effect of Bmi-1 overexpression and silencing on SHH and Wnt/catenin signaling pathways and to define the underlying mechanism of SHH-Bmi-1--catenin interaction at transcriptional and translational level in human CaP cells.

Sub-aim: To determine the effect of Bmi-1 gene overexpression and silencing on the molecules associated with SHH signaling and on the transcriptional activities of Gli-1-Luc and Bcl-2-luc reporter (SHH pathway) in human CaP cells. Status: This project was transferred from University of Wisconsin to University of Minnesota. The wok on this project was suspended at least for 3 months. This was due to the process of transfer of funding from PI's earlier work place (University of Wisconsin) to PI's new work place (University of Minnesota). The award was relinquished by University of Wisconsin on 01/31/2010. The University of Minnesota set up a pre-award fund (for this project ) on 4/13/2010. This caused a delay in executing and completing the some of the work as proposed under Task-2 of the proposal.
Experiments are underway and following tasks have been completed: overexpression. Among 24 clones generated, we selected 3 clones those exhibited the highest degree of Bmi-1 expression level.
(ii). Stable Bmi-1-silenced CaP Cell Generation by vector-based shRNA: Stable CaP cells lines exhibiting
least or no Bmi-1 expression levels have been generated. For this purpose LNCaP cells were stably transfected with vector-based shRNA plasmid, pGeneCLIP-Bmi-1-shRNA. The shRNA plasmids are designed using an experimentally validated algorithm. These constructs specifically knock down the expression of specific genes by RNA interference and allow for enrichment or selection of transfected cells.
Each vector expresses a short hairpin RNA, or shRNA, under control of the U1 promoter and neomycin gene. Neomycin resistance permits selection of stably transfected cells. The ability to select or track and enrich shRNA-expressing cells brings RNA interference to cell lines with lower transfection efficiencies.
Unlike siRNA, plasmid-based shRNA also provide a renewable source of RNA interference reagent. The transfections were performed by Lipofactamine method. LNCaP cells were selected in presence of neomycin analogue G418 (300 g/ml). The selection of Bmi-1-overexpressing LNCaP cells under G418 continued for 8 weeks. Cells were tested for Bmi-1 expression. Among 20 clones generated, we selected 3 clones those exhibited the least or no Bmi-1 expression level.
(iii). Use of Stable CaP Cells for Tumor Studies: We plan to use Bmi-1-overexpressing LNCaP clones and
Bmi-1-silenced LNCaP clones for tumor studies in xenograft mouse models. We plan to test the tumorigenic potential of Bmi-1-overexpressing and Bmi-1-silenced LNCaP clones in athymic nude mice. To achieve this objective, we have very recently procured athymic nude mice from Harlen Tek laboratories. The animals are under acclimatization phase since their arrival in our animal facility.
Reportable Outcome
Bmi-1 protein expression in normal and CaP cells:
As an attempt towards identifying the expression of Bmi-1
in CaP progression, we first measured protein expression levels by immunoblot analysis in several human prostate carcinoma cell lines, LNCaP, DU-145 and PC-3, and compared them to NHPE and RWPE-1 cells.
Among three cell lines used, LNCaP is androgen-sensitive whereas DU-145 and PC-3 are androgenindependent. The choice of these cells was based on the fact that 80% CaP patients present with androgendependent disease at the time of diagnosis which later transforms into more aggressive, androgen-independent disease (14-15 and references therein). As shown in Figure 1A , all CaP cell lines exhibited a higher expression of Bmi-1 protein than in normal prostate epithelial cells. When the protein expression of Bmi-1 was compared among three cancer lines, based on the densitometric analysis of the immunoblots, highly aggressive PC-3 cells and DU145 exhibited 2.5-fold (p<0.001) higher expression than in LNCaP cells. These data suggest a possibility that expression of Bmi-1 protein may be correlated with disease progression and may play a role in aggressiveness of human CaP.
Immunohistochemical analysis of Bmi-1 protein in normal and CaP specimens:
In the next series of experiments, we used immunoperoxidase to determine Bmi-1 protein expression in specimens of age-matched normal and CaP representing all tumor stages. In the first experiment, a total of 80 samples were obtained. The staining intensity in tissue specimens were scored on a scale of 0-3. The staining pattern of Bmi-1 protein was compared in grade 1, grade 2 and grade 3 CaP specimens. The mean Bmi-1 expression was 1.5 ± 0.15 (mean ± S.E; n = 25) in grade 1 specimens, 2.5 ± 0.20 (mean ± S.E; n = 25) in grade 2 specimens, and 2.9 ± 0.15 (mean ± S.E; n = 30 ) in grade 3 specimens ( Fig. 1B) . These data show a progressive increase of Bmi-1 protein expression corresponding with increasing tumor grade in human CaP ( Figure 1B ). Figure 3B ). These data suggest the importance of Bmi-1 in the growth of CaP cells.
Bmi-1 knockdown and Bmi-1 overexpression:
Effect of Bmi-1 knockdown and Bmi-1-overexpression on of proliferation of CaP cells. We investigated
whether Bmi-1 regulates the proliferation process of CaP cells. We employed a two-way approach where Bmi-1 was either knocked down or overexpressed in CaP cells and such CaP cells were later assessed for their proliferative and clonogenic potential by employing 3 [H]thymidine uptake assay. Firstly, LNCaP, PC-3 and DU145 cells were transfected with Bmi1-siRNA (100 nM). To investigate the effect of Bmi-1 gene suppression on the rate of proliferation of LNCaP, DU145 and PC-3 cells, we performed 3 [H]thymidine uptake assay.
Suppression of Bmi1-1 expression resulted in the decreased rate of proliferation of CaP cells ( Figure 4A ). Bmi-1-overexpressing CaP cells displayed significantly increased rate of proliferation ( Figure 4B ).
Colony formation assay is used as a marker for proliferation of cells under ex-vivo conditions. Next, we investigated the effect of suppression of Bmi-1 on the clonogenic potential of CaP cells in ex-vivo conditions.
For this purpose we employed a soft agar colony assay and assessed the clonogenic potential of CaP cells transfected with Bmi-1 siRNA and pbabe-Bmi-1 plasmid. Bmi-1 knockdown resulted in a significant reduction in the number of colonies formed by CaP cells as compared to control siRNA-treated cells ( Figure 5A ).
However, Bmi-1-overexpressing CaP cells exhibited increased clonogenicity potential as is evident from an increase in the average number of colonies formed by Bmi-1-overexpressing cells ( Figure 5B ). These data suggested that Bmi-1 confers proliferative attributes to the CaP cells.
Effect of Bmi-1 gene knockdown on CaP-associated genes:
Next, we investigated the mechanism through which Bmi-1 controls the proliferation and survival of CaP cells. We performed a focused microarray analysis of 288 well-characterized proliferation and survival-associated genes in Bmi-1 suppressed-CaP cells. The list of genes that were observed to exhibit changes in their expression pattern in response to Bmi-1 knockdown in CaP cells is presented in Table 1 . Most notably, we observed that suppression of Bmi-1 gene in CaP cells caused a significant reduction (> 95%) in the expression of Cyclin D1, Bcl-2, urokinase plasminogen activator (uPA), matrix metalloproteinase (MMP)-9 and nuclear factor kappa B (NFB) ( Table 1) . We also observed an increased expression of p16, p15 and TIMP-3 (Table 1 ). Since Cyclin D1 and Bcl-2 were highly responsive to
Bmi-1 gene suppression; we selected these genes for further biochemical studies.
Effect of Bmi-1 gene knockdown and Bmi-1-overexpression on Cyclin-D1 and Bcl-2 Levels: Increased
Cyclin-D1 activity and Bcl-2 are considered important for the increased proliferation and survival of cancerous cells (16) (17) (18) (19) (20) (21) . Next, we analyzed the effect of Bmi-1 gene-suppression on the expression of cyclin D1 and Bcl-2 in LNCaP, DU145 and PC-3 cells. Bmi-1 knockdown caused a decrease in the expression level of Cyclin D1
and Bcl-2 protein in CaP cells ( Figure 6A ). Next we determined the effect of Bmi-1 overexpression on the expression levels of cyclin D1 and Bcl-2. CaP cells transfected with Bmi-1 construct exhibited a significant increase in the expression level of cyclin D1 and Bcl-2 protein ( Figure 6B ). These data were consistent with microarray data suggesting a possible association between the Bmi-1, Cyclin D1 and Bcl-2 during progression of human CaP.
Effect of Bmi-1-overexpression on transcriptional activation of TCF-responsive element: Cyclin D1
expression has been reported to be regulated by Wnt signaling (22) . Since we observed that Bmi-1 also regulate Cyclin D1 expression, we asked whether there is any association between Bmi-1 and Wnt signaling. Next we investigated effect of Bmi-1 overexpression on Wnt signaling by evaluating the transcriptional activation of Tcfresponsive element (marker of Wnt signaling) by employing luciferase reporter assay. It is noteworthy that
Bmi-1 over-expression caused an increase in the transcriptional activation of TCF-responsive element suggesting that Bmi-1-induced Cyclin D1 expression might be through the activation of Wnt signaling ( Figure   7 ). This is the first report where Bmi-1 is shown to regulate Wnt signaling. To fully understand the association between Bmi-1 and Wnt signaling, the work is underway.
Effect of Bmi-1 overexpression on the replicative life of normal prostate epithelial cells (PrEC):
Transfection of pbabe-Bmi-1 plasmid significantly increased the replicative life of PrEC cells upto 8 passages which generally enters into a stage of senescence after 4-5 divisions (Figure 8 ).These data suggest that Bmi-1 possess the potential to drive normal cells towards proliferation.
Effect of Sonic hedgehog (SHH) signaling inhibition on Bmi-1-silenced and Bmi-1 overexpressing CaP cells: Keeping in view that (1) modulations in Bmi-1 expression cause modulations in the expression levels of
anti-apoptotic protein Bcl-2 as shown in Figure 6 , and (2) the transcriptional activation of Bcl-2 is known to be regulated by sonic hedgehog signaling, we next determined the effect of cyclopamine (SHH signaling inhibitor) treatment on the growth and viability of LNCaP and PC-3 cells exhibiting varied expression levels of Bmi-1. To achieve our objective, Bmi-1-suppressed and Bmi-1 overexpressing CaPs were treated with Cyclopamine for 12
h. As is shown in Figure 9A , Cyclopamine treatment was observed to cause 35% reduction of viability of control CaP cells (transfected with scrambled siRNA alone). Bmi-1-deficient CaP cells were significantly responsive to cyclopamine treatment and 90% reduction in the viability of Bmi-1-suppressed cells was observed ( Figure 9A ). On the contrary, Bmi-1-overexpressing CaP cells were non-responsive to Cyclopamine treatment ( Figure 9B ). Bmi-1 over-expression was observed to abrogate the effect of Cyclopamine treatment in CaP cells ( Figure 9B ). When tested for Bcl-2 protein, Bmi-1 overexpressing CaP cells were observed to exhibit elevated levels and the reverse was observed in Bmi-1 deficient LNCaP cells when were treated with cyclopamine ( Figure 10A-B) . These data suggest that Bmi-1 confers the survivability characteristics to CaP cells by inducing the expression levels Bcl-2 (the anti-apoptotic protein) post chemotherapeutic treatment (Figures 9 & 10) . These data provide evidence that in chemoresistant CaP cells, Bcl-2 activation is SHH-independent.
Analysis of Promoter Region of Bcl-2 gene for TCF-transcriptional factor binding sites:
Since we observed that Bmi-1 induces the activation of (1) TCF, transcriptional factor and (2) Bcl-2, the anti-apoptotic factor, we investigated the possibility of interaction among Bmi-1, Bcl-2 and TCF. We investigated possible binding sites on the promoter region of Bcl-2 gene by employing web-based TESS analysis. Interestingly, Bcl-2 promoter region exhibited multiple sites where TCF transcriptional factor possess the affinity to bind (Figure 11 ). These data suggested that Bcl-2 is a target of Wnt signaling.
Effect of TCF-knockdown on the transcriptional activation of Bcl-2 in CaP cells: On the basis of our
observations that (1) Figure 12 ). These data suggest that Bcl-2 expression is regulated by Wnt signaling in CaP cells. overexpressing plasmid, Bcl-2 promoter activity was observed to be significantly restored. These data suggest that Bmi-1 has the potential to induce Bcl-2 expression in CaP cells. Further, when tested, these cells also exhibit restored Tcf-transcriptional activation.
Effect of Bmi-1 introduction on Bcl-2 promoter activity in TCF-silenced LNCaP cells: We asked if
Effect of Bmi-1 introduction on Bcl-2 promoter activity in LNCaP cells pretreated with SHH inhibitor:
We asked if Bmi-1 introduction in LNCaP cells pretreated with SHH inhibitor, Cyclopamine (that reduces Bcl-2 levels) could restore Bcl-2 transcriptional activation in these cells. For this purpose LNCaP cells were treated with Cyclopamine for 24h to inhibit SHH pathway activation thus downregulating the levels of the target protein Bcl-2 (SHH target). These cells were transfected with Bcl-2-luc construct and Bcl-2 promoter activity was measured by reporter assay. As expected, Cyclopamine-treated LNCaP cells exhibited reduced Bcl-2 promoter activity. However, when a set of cyclopamine-treated LNCaP cells (cultured under similar conditions)
were transfected again with Bmi-1-overexpressing plasmid, Bcl-2 promoter activity was observed to be significantly restored. These data suggest that Bmi-1 has the potential to induce Bcl-2 expression in CaP cells even under extreme conditions (Bcl-2 ablation in this case). We hypothesize that this might be one of the potential mechanisms through Bmi-1 confers survivability to cancerous cells undergoing chemotherapy. To summarize, we show that Bmi-1 confers the survivability to chemoresistant CaP cells and identified Bcl-2 as a target of Wnt signaling in CaP cells. To understand the mechanism through which CaP cells survive even after chemotherapy, and the role of Bmi-1 as a potential target for chemotherapy for CaP, further studies are underway in my laboratory.
Conclusion
Recent experimental observations documented an increased Bmi-1 expression in human non-small-cell lung cancer, human breast carcinomas, and established breast cancer cell lines, suggesting that an oncogenic role of Bmi-1 activation may be extended beyond leukemia and, perhaps, may affect progression of the epithelial malignancies as well (8) (9) (10) (11) (12) (13) (23) (24) . Over expression of Bmi-1 is reported to confer invasive potential to glioma and breast cancer cells, and cause malignant phenotype in rat and human cancer cells, however, the role of Bmi-1 in human CaP metastasis is yet to be elucidated (8) (9) (10) (11) (12) (13) (23) (24) . In the present study, we observed that Bmi-1 gene controls the invasiveness and growth of human CaP cells under in vitro and in vivo conditions through the regulation of Cyclin D1 and Bcl-2. To our knowledge, this report is the first demonstration that Bmi-1 regulates Cyclin D1 and Bcl-2 in human CaP cells.
In our preliminary studies (data generated in the first year of the project), we show that Bmi-1 protein levels are elevated in CaP patients if high grade tumor. Further, we also show that overexpression of Bmi-1 gene increases the rate of proliferation and invasion of CaP cells and its suppression reverses this effect. We provide evidence that suppression of Bmi-1 gene reduces the proliferative and clonogenic potential of human CaP cells. On the contrary, overexpression of Bmi-1 was observed to increase the clonogenic potential of human CaP cells.
Cyclin D1 is a critical protein that is required for cell division and proliferation. Cyclin D1 levels have been reported to be increased during several cancer types (25) (26) (27) (28) (29) (30) (31) (32) (33) . CaP patients have been shown to exhibit increased Cyclin D1 levels (34) (35) , however the mechanism through which Cyclin D1 levels are altered during cancer development is not fully understood. In this study, we provide evidence that Cyclin D1 is regulated by Bmi-1 in CaP cells. It is noteworthy that CaP cells deficient in Bmi-1 exhibited decreased Cyclin D1 levels. However,
Bmi-1-overexpressing CaP cells displayed an increase in Cyclin D1 protein levels suggesting significance of
Bmi-1 protein for Cyclin D1 expression in CaP cells.
To understand the mechanism through which Bmi-1 regulates Cyclin D1, we studied critical pathways which are known to be associated with Cyclin D1 expression. This includes Wnt/-catenin signaling pathway. We asked whether Bmi-1 has any association with Wnt/-catenin signaling (which is itself reported to control Cyclin D1). Interestingly, we found that Bmi-1 overexpression causes an increase in the transcriptional activation of TCF-responsive element (a bio-marker of Wnt signaling) in CaP cells. These data are highly significant. This finding is novel and is the first report showing that Bmi-1 regulates Wnt signaling in CaP cells.
Wnt signaling is report to be involved in the proliferation and chemoresistance of CaP cells. Further work to understand the mechanistic role in Wnt signaling in CaP cells is underway and will be completed by the end of 2 nd year of the proposed project.
Bcl-2 protein is known to play an important role in the survival of cancer cells by conferring anti-apoptotic potential to cells (18) (19) (20) (21) . Bcl-2 levels are reported to be high in cancer cells including CaP cells (36) . In the current study, we provide evidence that Bmi-1 is associated with expression of Bcl-2 in CaP cells. Bmi-1deficient CaP cells exhibited decreased Bcl-2 levels while as Bmi-1-overexpressing CaP cells exhibited increased Bcl-2 levels. As evident from reports which suggest that Bmi-1 confers renewability or stemness characteristics to cancer cells and Bcl-2 confers survivability characteristics to cancer cells, our data showing association between Bmi-1 and Bcl-2 is highly significant. However, it would be important to fully understand the mechanism through which Bmi-1 regulates Bcl-2 in CaP cells. To understand the mechanism through which (1) Bmi-1-induces Wnt signaling, and (2) Wnt-signaling regulate Bcl-2 expression in CaP cells, we have planned experiments and some of experiments are in progress. Vascular endothelial growth factor (VEGF) Matrix metalloproteinase -9 (MMP-9) Nuclear factor kappa B 1(NFκB1) HIF-1 Insulin growth factor 1(IGF1) Insulin growth factor 1(IGF2) 
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